Generic MS Drug Development Was Protected, Sandoz Says

Law360, New York (April 18, 2013, 8:45 PM EDT) -- Sandoz Inc. asked a New York federal judge Wednesday to toss Teva Pharmaceuticals Industries Ltd.'s patent infringement suit, saying its use of a patented process as it developed a generic form of multiple sclerosis drug Copaxone was protected by the safe harbor exemption.

Teva sued Sandoz in December 2009 for using the polypeptide TP-116 in its preparation of generic glatiramer acetate — thereby allegedly infringing on four Teva patents — but Sandoz said Wednesday that it was allowed to use the chemical compound under the research...
To view the full article, register now.